<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02201316</url>
  </required_header>
  <id_info>
    <org_study_id>200940</org_study_id>
    <nct_id>NCT02201316</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions</brief_title>
  <official_title>An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (Gasmotin) in Healthy Adult Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the relative bioavailability of two candidate formulations of&#xD;
      mosapride citrate 5mg tablets compared the reference product GASMOTIN (mosapride citrate 5mg)&#xD;
      from Dainippon Pharmaceutical Company in healthy adult subjects. This will be an open-label,&#xD;
      randomised, single dose, three-way crossover, six sequence study. Subjects will receive a&#xD;
      single oral dose separated by at least 7 days and no greater than 14 days washout period.&#xD;
      This study is required to select a candidate mosapride citrate (GR107719B) formulation for&#xD;
      further development and provide data to allow the design of a future pivotal bioequivalence&#xD;
      study. The candidate formulations will be compared with the innovator GASMOTIN. GASMOTIN is a&#xD;
      trademark of Dainippon Sumitomo Pharmaceutical Company.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2014</start_date>
  <completion_date type="Actual">March 18, 2014</completion_date>
  <primary_completion_date type="Actual">March 18, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of pharmacokinetics (PK) parameters of mosapride following administration of two candidate tablet formulations of mosapride citrate (GR107719B) relative to reference mosapride citrate (GASMOTIN)</measure>
    <time_frame>Day 1 of each treatrment period (Pre dose and 0.25 hour (h), 0.5 h, 0.75 h, 1 h, 1.33 h, 1.67 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h post dose)</time_frame>
    <description>PK parameters include: area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time [AUC(0-infinity)] and area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of two candidate tablet formulations of mosapride citrate (GR107719B) relative to reference mosapride citrate tablets (GASMOTIN)</measure>
    <time_frame>Day 1 of each treatrment period (Pre dose and 0.25 hour (h), 0.5 h, 0.75 h, 1 h, 1.33 h, 1.67 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h post dose)</time_frame>
    <description>PK parameters include: Percentage of AUC (0-∞) obtained by extrapolation (%AUCex) time of occurrence of Cmax (tmax), terminal phase half-life (t1/2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessment as assessed by review of adverse events (AEs)</measure>
    <time_frame>Up to 51 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessment as assessed by vital signs</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, and pulse rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability assessment as assessed by clinical laboratory values</measure>
    <time_frame>Up to 51 days</time_frame>
    <description>Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Gastritis</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference mosapride citrate (GASMOTIN)</intervention_name>
    <description>Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.</description>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GR107719B (Formulation 1)</intervention_name>
    <description>GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.</description>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GR107719B (Formulation 2)</intervention_name>
    <description>GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.</description>
    <arm_group_label>Sequence 1 (ABC)</arm_group_label>
    <arm_group_label>Sequence 2 (ACB)</arm_group_label>
    <arm_group_label>Sequence 3 (BAC)</arm_group_label>
    <arm_group_label>Sequence 4 (BCA)</arm_group_label>
    <arm_group_label>Sequence 5 (CAB)</arm_group_label>
    <arm_group_label>Sequence 6 (CBA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and females aged between 18 and 65 years of age inclusive, at the time of signing&#xD;
             the informed consent.&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s)&#xD;
             which is/are not specifically listed in the inclusion or exclusion criteria, outside&#xD;
             the reference range for the population being studied may be included only if the&#xD;
             Investigator in consultation with the GSK Medical Monitor if required agree and&#xD;
             document that the finding is unlikely to introduce additional risk factors and will&#xD;
             not interfere with the study procedures.&#xD;
&#xD;
          -  Body weight &gt;= 50 kilogram (kg) and body mass index within the range 19 - 24.9 kg/m^2&#xD;
             (inclusive).&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of: Non-childbearing potential&#xD;
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy for&#xD;
             this definition, &quot;documented&quot; refers to the outcome of the investigator's/designee's&#xD;
             review of the subject's medical history for study eligibility, as obtained via a&#xD;
             verbal interview with the subject or from the subject's medical records; or&#xD;
             postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a&#xD;
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40&#xD;
             milli-international units per milliliter (MlU/mL) and estradiol &lt; 40 picograms per&#xD;
             mililiter (pg/mL) [&lt;147 picomole per liter] is confirmatory]. Females on hormone&#xD;
             replacement therapy (HRT) and whose menopausal status is in doubt will be required to&#xD;
             use one of the contraception methods if they wish to continue their HRT during the&#xD;
             study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal&#xD;
             status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will&#xD;
             elapse between the cessation of therapy and the blood draw; this interval depends on&#xD;
             the type and dosage of HRT. Following confirmation of their post-menopausal status,&#xD;
             they can resume use of HRT during the study without use of a contraceptive method;&#xD;
             Child-bearing potential with negative pregnancy test as determined by serum human&#xD;
             chorionic gonadotrophin (hCG) test at screening or prior to dosing AND; Agrees to use&#xD;
             one of the contraception methods listed in protocol for an appropriate period of time&#xD;
             (as determined by the product label or investigator) prior to the start of dosing to&#xD;
             sufficiently minimize the risk of pregnancy at that point. Female subjects must agree&#xD;
             to use contraception until the follow-up contact visit; OR has only same-sex partners,&#xD;
             when this is her preferred and usual lifestyle.&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use one of&#xD;
             the contraception methods listed in Protocol. This criterion must be followed from the&#xD;
             time of the first dose of study medication until the follow-up contact visit.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
          -  Alanine aminotransferase, alkaline phosphatase and bilirubin &lt;=1.5x upper limit of&#xD;
             normal (ULN) (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated&#xD;
             and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Based on single or averaged corrected QT interval (QTc) values of triplicate&#xD;
             electrocardiograms obtained over a brief recording period: QTcF &lt; 450 msec&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as: An&#xD;
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is&#xD;
             equivalent to 8 gram of alcohol: a half-pint (approximately 240 milliliter [mL]) of&#xD;
             beer, 1 glass (100 mL) of wine or 1 (25 mL) measure of spirits.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Gastrointestinal disease or with gastrointestinal surgical history which can affect&#xD;
             the absorption of the investigational product.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for Human Immunodeficiency Virus (HIV) antibody.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum hCG test at screening or prior to&#xD;
             dosing.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 90 day period.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 90 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2014</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy adult human subjects</keyword>
  <keyword>Mosapride citrate anhydrous</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02201316
org study id: 200940
nct id: NCT02201316
lead sponsor: 
has dmc: No
This study aims to determine the relative bioavailability of two candidate formulations of
      mosapride citrate 5mg tablets compared the reference product GASMOTIN (mosapride citrate 5mg)
      from Dainippon Pharmaceutical Company in healthy adult subjects. This will be an open-label,
      randomised, single dose, three-way crossover, six sequence study. Subjects will receive a
      single oral dose separated by at least 7 days and no greater than 14 days washout period.
      This study is required to select a candidate mosapride citrate (GR107719B) formulation for
      further development and provide data to allow the design of a future pivotal bioequivalence
      study. The candidate formulations will be compared with the innovator GASMOTIN. GASMOTIN is a
      trademark of Dainippon Sumitomo Pharmaceutical Company.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Composite of pharmacokinetics (PK) parameters of mosapride following administration of two candidate tablet formulations of mosapride citrate (GR107719B) relative to reference mosapride citrate (GASMOTIN)
time frame: Day 1 of each treatrment period (Pre dose and 0.25 hour (h), 0.5 h, 0.75 h, 1 h, 1.33 h, 1.67 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h post dose)
description: PK parameters include: area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time [AUC(0-infinity)] and area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)]
measure: PK parameters of two candidate tablet formulations of mosapride citrate (GR107719B) relative to reference mosapride citrate tablets (GASMOTIN)
time frame: Day 1 of each treatrment period (Pre dose and 0.25 hour (h), 0.5 h, 0.75 h, 1 h, 1.33 h, 1.67 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 16 h, 24 h post dose)
description: PK parameters include: Percentage of AUC (0-∞) obtained by extrapolation (%AUCex) time of occurrence of Cmax (tmax), terminal phase half-life (t1/2).
measure: Safety and tolerability assessment as assessed by review of adverse events (AEs)
time frame: Up to 51 days
measure: Safety and tolerability assessment as assessed by vital signs
time frame: Up to 51 days
description: Vital sign measurements will include systolic and diastolic blood pressure, and pulse rate.
measure: Safety and tolerability assessment as assessed by clinical laboratory values
time frame: Up to 51 days
description: Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters.
arm group label: Sequence 1 (ABC)
arm group type: Experimental
description: Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
arm group label: Sequence 2 (ACB)
arm group type: Experimental
description: Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
arm group label: Sequence 3 (BAC)
arm group type: Experimental
description: Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
arm group label: Sequence 4 (BCA)
arm group type: Experimental
description: Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
arm group label: Sequence 5 (CAB)
arm group type: Experimental
description: Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
arm group label: Sequence 6 (CBA)
arm group type: Experimental
description: Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
intervention type: Drug
intervention name: Reference mosapride citrate (GASMOTIN)
description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
arm group label: Sequence 1 (ABC)
arm group label: Sequence 2 (ACB)
arm group label: Sequence 3 (BAC)
arm group label: Sequence 4 (BCA)
arm group label: Sequence 5 (CAB)
arm group label: Sequence 6 (CBA)
intervention type: Drug
intervention name: GR107719B (Formulation 1)
description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
arm group label: Sequence 1 (ABC)
arm group label: Sequence 2 (ACB)
arm group label: Sequence 3 (BAC)
arm group label: Sequence 4 (BCA)
arm group label: Sequence 5 (CAB)
arm group label: Sequence 6 (CBA)
intervention type: Drug
intervention name: GR107719B (Formulation 2)
description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
arm group label: Sequence 1 (ABC)
arm group label: Sequence 2 (ACB)
arm group label: Sequence 3 (BAC)
arm group label: Sequence 4 (BCA)
arm group label: Sequence 5 (CAB)
arm group label: Sequence 6 (CBA)
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: India
responsible party type: Sponsor
mesh term: Gastritis
mesh term: Mosapride